APM
PACB icon

Avidity Partners Management’s Pacific Biosciences PACB Stock Holding History

Avidity Partners Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-675,000
Closed -$2.53M – 101
2024
Q1 		$2.53M Buy
+675,000
New +$3.95M 0.08% 85
2023
Q4 		– Sell
-1,034,294
Closed -$8.64M – 83
2023
Q3 		$8.64M Sell
1,034,294
-3,303,106
-76% -$37.7M 0.35% 67
2023
Q2 		$57.7M Buy
4,337,400
+524,800
+14% +$6.38M 2.01% 18
2023
Q1 		$44.1M Buy
+3,812,600
New +$37.9M 1.47% 27

Other funds holding PACB

ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.39B AUM 10.34% 1-Year Est. Return
Edmond de Rothschild Holding
Edmond de Rothschild Holding Chambesy, Switzerland $7.59B AUM 23.44% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Avidity Partners Management's PACB Position: Q2 2024 in Review

Avidity Partners Management sold out of Pacific Biosciences (PACB) in Q2 2024, closing a stake of 675,000 shares — an estimated $2.53M sold.

Avidity Partners Management first reported a position in PACB in Q1 2023 and held it in 4 quarters. The position peaked at $57.7M in Q2 2023. 229 funds tracked by Wall St. Rank hold PACB as of Q2 2024.

  • Avidity Partners Management reported no remaining Pacific Biosciences position as of Q2 2024 after selling out during the quarter.
  • Avidity Partners Management sold 675,000 Pacific Biosciences shares in Q2 2024, an estimated $2.53M.
  • Avidity Partners Management first reported a position in Pacific Biosciences in Q1 2023 and held it in 4 quarters.
  • Avidity Partners Management's Pacific Biosciences position peaked at $57.7M in Q2 2023.
  • 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2024.

Based on Avidity Partners Management's 13F filing for Q2 2024, filed 14 Aug 2024.